Effectiveness of combination of pharmachothrapy with metacognitive therapy versus pharmachotherapy in patient with posttraumatic stress disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017060828504N2

Enrollment

Registered

2017-06-27

Start date

2009-04-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic stress disorder. Post-traumatic stress disorder

Interventions

Intervention 1: Intervention group1: (Drug treatment) Patients receive medication in addition, questionnaires: Clincian-Adminestered PTSD Scale (CAPS), beck anxiety (BAI), beck depression(BDI-II), Me

Treatment - Drugs

Treatment - Other

Intervention group1: (Drug treatment) Patients receive medication in addition, questionnaires: Clincian-Adminestered PTSD Scale (CAPS), beck anxiety (BAI), beck depression(BDI-II), Metacognition ques

Intervention group2: Combination of pharmachothrapy with metacognitive therapy: Subjects complete CAPS, BDI-II, BAI, SUDs, MCQ-30, GAFs at pre test, post test and follow up.

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Having a chronic PTSD based on DSM-4 criterias? Do not receive psychological treatment before the study? In the case of using medicine, the possibility of keeping the type and dose of drugs during the study? Minimum 18 years and maximum 50 years? with at least third level education? The patient agreed to participate in the study and signed a written consent. Exclusion criteria: having a psychotic disorder and substance use disorder? Having full criteria for personality disorder in Axis II? There are risks for the patient such as having serious thoughts of suicide.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Subjective unit of distress. Timepoint: Pre test, Post test, Follow up ( 1month), Follow up ( 2 month). Method of measurement: Subjective unit of distress scale.;Anxiety. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: Beck anxiety inventory.;PTSD Signs. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: PTSD Inventory.;Depression. Timepoint: Pre test, Post test, Follow up(1 month), Follow up( month). Method of measurement: Beck depression inventory.;Metacognition. Timepoint: Pre test, Post test, Follow up(1 month), Follow up(2 month). Method of measurement: Metacognition Questionnaire-30 (MCQ-30).;General functioning. Timepoint: Pre test, Post test, Follow up ( 1 month),Follow up (2 month). Method of measurement: General assessment of functioning.	—

Measure

Time frame

Subjective unit of distress. Timepoint: Pre test, Post test, Follow up ( 1month), Follow up ( 2 month). Method of measurement: Subjective unit of distress scale.;Anxiety. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: Beck anxiety inventory.;PTSD Signs. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: PTSD Inventory.;Depression. Timepoint: Pre test, Post test, Follow up(1 month), Follow up( month). Method of measurement: Beck depression inventory.;Metacognition. Timepoint: Pre test, Post test, Follow up(1 month), Follow up(2 month). Method of measurement: Metacognition Questionnaire-30 (MCQ-30).;General functioning. Timepoint: Pre test, Post test, Follow up ( 1 month),Follow up (2 month). Method of measurement: General assessment of functioning.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Dadashi

Zanjan University of Medical Sciences

vida.yousefi@zums.ac.ir; mohsendadashi@zums.ac.ir+98 242433534500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026